Stock Price Movement and Market Context
On 30 Jan 2026, Epigral Ltd’s share price touched an intraday high of Rs.1053.45, representing a 2.33% gain for the day. However, this modest uptick followed four consecutive days of declines, culminating in the new 52-week low of Rs.1010.85. The stock outperformed its sector by 1.33% on the day but continues to trade below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signalling a sustained bearish trend.
In comparison, the Sensex opened lower at 81,947.31, down 619.06 points (-0.75%), and was trading at 82,034.95 (-0.64%) during the same session. The benchmark index remains below its 50-day moving average, although the 50DMA is positioned above the 200DMA, indicating mixed technical signals for the broader market.
Long-Term Performance and Valuation Metrics
Over the past year, Epigral Ltd’s stock has declined by 41.48%, significantly underperforming the Sensex, which posted a 6.92% gain over the same period. The stock’s 52-week high was Rs.2114.30, underscoring the extent of the recent price erosion. This underperformance extends beyond the last year, with the stock lagging the BSE500 index over the last three years, one year, and three months.
Epigral’s Market Capitalisation Grade stands at 3, reflecting a mid-tier market cap status. The company’s Mojo Score is 31.0, with a current Mojo Grade of Sell, upgraded from a previous Strong Sell rating on 26 Dec 2025. This adjustment indicates a slight improvement in outlook, though the overall sentiment remains cautious.
Perfect timing to enter! This Small Cap from IT - Software just turned profitable with growth momentum clearly building up. Get in before the broader market notices!
- - New profitability achieved
- - Growth momentum building
- - Under-the-radar entry
Financial Performance and Profitability Trends
Epigral Ltd’s financial results have reflected challenges in recent quarters. The company reported a Profit Before Tax (PBT) excluding other income of Rs.67.91 crore in the September 2025 quarter, representing a 45.2% decline compared to the average of the previous four quarters. Similarly, Profit After Tax (PAT) for the same period was Rs.51.22 crore, down 52.6% relative to the prior four-quarter average.
Interest expenses for the nine months ended September 2025 rose by 37.3% to Rs.56.98 crore, indicating increased financing costs. These factors have contributed to the subdued earnings momentum and weighed on investor sentiment.
Operational Efficiency and Debt Metrics
Despite the earnings contraction, Epigral Ltd maintains a strong operational efficiency profile. The company’s Return on Capital Employed (ROCE) stands at a robust 23.19%, signalling effective utilisation of capital resources. Additionally, the Debt to EBITDA ratio is a modest 1.34 times, reflecting a manageable debt burden and a solid capacity to service liabilities.
Valuation metrics also suggest the stock is trading at a discount relative to its peers. With a ROCE of 19.3% and an Enterprise Value to Capital Employed ratio of 1.9, the company’s valuation appears attractive on a relative basis. The Price/Earnings to Growth (PEG) ratio is 0.3, indicating that the stock’s price decline has outpaced profit growth, which rose by 37.1% over the past year.
Considering Epigral Ltd? Wait! SwitchER has found potentially better options in Specialty Chemicals and beyond. Compare this small-cap with top-rated alternatives now!
- - Better options discovered
- - Specialty Chemicals + beyond scope
- - Top-rated alternatives ready
Shareholding and Sector Positioning
Epigral Ltd operates within the Specialty Chemicals industry, a sector characterised by cyclical demand and sensitivity to raw material costs. The company’s majority shareholding is held by promoters, providing a stable ownership structure. However, the stock’s recent performance and valuation metrics reflect the challenges faced in sustaining growth and profitability amid sector headwinds.
While the stock has shown some resilience with a slight gain today after a series of declines, it remains to be seen how it will navigate the pressures from both market conditions and internal financial dynamics.
Summary of Key Metrics
To summarise, Epigral Ltd’s stock has reached a new 52-week low of Rs.1010.85, down significantly from its 52-week high of Rs.2114.30. The company’s Mojo Grade was upgraded from Strong Sell to Sell on 26 Dec 2025, reflecting a marginally improved outlook. Despite a strong ROCE of 23.19% and manageable debt levels, recent quarterly earnings have declined sharply, with PBT and PAT falling by over 45% and 52% respectively. Interest costs have increased by more than a third over nine months, adding to financial pressures.
Trading below all major moving averages, the stock’s technical indicators remain weak, and its one-year return of -41.48% contrasts starkly with the Sensex’s positive 6.92% performance. Valuation metrics suggest the stock is discounted relative to peers, with a PEG ratio of 0.3 and an Enterprise Value to Capital Employed ratio of 1.9.
Conclusion
Epigral Ltd’s recent price action and financial results highlight a period of subdued performance within the Specialty Chemicals sector. The stock’s new 52-week low underscores the challenges faced by the company in maintaining earnings growth and market confidence. While operational efficiency and debt servicing remain strengths, the overall trend reflects a cautious environment for the stock amid broader market pressures.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
